12% CONVERTIBLE PROMISSORY NOTE DUE October 19 2019Rasna Therapeutics Inc. • February 14th, 2019 • Pharmaceutical preparations • New York
Company FiledFebruary 14th, 2019 Industry JurisdictionTHIS CONVERTIBLE PROMISSORY NOTE is one of a series of duly authorized and validly issued Notes of Rasna Therapeutics, Inc., a Nevada corporation, (the “Borrower”), having its principal place of business at 420 Lexington Avenue, Suite 2525, New York, New York 10170, due October 19, 2019 (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).